MDL-3194 • Abbott / St. Jude Medical

Abbott Spinal Cord Stimulator Lawsuit

Updated November 2, 2026. Abbott (formerly St. Jude Medical) issued a Class I spinal cord stimulator recall in July 2023 covering 155,028 U.S. devices. Abbott cases now have their own MDL: on October 2, 2026, after its September 24 hearing session, the JPML centralized them as MDL-3194 in the Northern District of Illinois before Judge Lindsay C. Jenkins. There is no verdict and no settlement in spinal cord stimulator litigation against any manufacturer.

Last Updated: November 2, 2026
6 min read
JPML Data Verified
7 sources cited

Key Takeaways

  • Abbott has a Class I SCS recall: July 18, 2023, an MRI-mode exit failure affecting 155,028 U.S. devices, 186 incidents, 73 injuries, 0 deaths. Boston Scientific's 2026 removal of unused Infinion CX leads is also Class I
  • Ignore the circulating 197,000 devices / 76 injuries figures; they do not match the FDA record
  • Abbott cases are now centralized as MDL-3194 in the Northern District of Illinois before Judge Lindsay C. Jenkins, by a JPML order of October 2, 2026, with 27 actions pending in the November 2026 report; an earlier denial had been a Section 1407 technicality (all four cases in one district), not a merits ruling
  • Also a Class II recall in May 2024 and October 2025; an April 2026 Surgery Mode correction is not yet FDA-classified
  • The one-year filing deadline risk from the Schiltz order may apply; there is no verdict and no settlement in the tort

Abbott's Class I SCS recall

On July 18, 2023, Abbott issued a recall the FDA classified as Class I, its most serious category, reserved for situations where a device could cause serious injury or death. The problem was a firmware error that could prevent the device from exiting MRI mode, which leaves stimulation switched off. The recall covered 155,028 U.S. devices and was associated with 186 reported incidents and 73 injuries, with no deaths. It is one of two Class I spinal cord stimulator recalls we have identified: in 2026 the FDA also classified Boston Scientific's removal of unused Infinion CX leads as Class I, a removal that the FDA said does not affect leads already implanted. The 2023 recall is part of why Abbott figures prominently in the litigation, and Abbott cases now have their own MDL, MDL-3194.

A note on numbers, because incorrect ones circulate. Some pages report roughly 197,000 devices or 76 injuries for this recall. Those figures do not match the FDA record, which is 155,028 devices and 73 injuries. We use the FDA figures.

The other recalls

Abbott also had a Class II recall in May 2024 concerning the interval between the elective replacement indicator and end of service, and a Class II recall in October 2025 involving Eterna Bluetooth functionality. Class II is a less severe category than Class I. Separately, an April 17, 2026 urgent medical device correction described as a Surgery Mode issue has been reported. That correction does not yet have an FDA-classified recall record, so we describe it as an unclassified correction and not as a recall until the FDA classifies it.

How Abbott got its own MDL

When the JPML created MDL-3181 on June 5, 2026, it declined to centralize the Abbott cases, but the reason was procedural. All four Abbott cases before the Panel were pending in the Northern District of Illinois, and the federal centralization statute (Section 1407) requires actions pending in different districts. As the Panel put it, it could not centralize cases against only Abbott on those facts. The denial was without prejudice, and a fresh centralization petition against Abbott was filed on June 22, 2026. A JPML Hearing Session Order filed August 14, 2026 set it for the Panel's September 24, 2026 hearing session in Chicago, and on October 2, 2026 the Panel granted it. The movants had asked for the Central District of California, alongside MDL-3181; the Panel instead sent the cases to the Northern District of Illinois, where Abbott is headquartered and ten actions were already pending, and assigned them to Judge Lindsay C. Jenkins as MDL-3194. It found the cases share questions about Abbott's use of the PMA-supplement process, its warnings, and its sales representatives' conduct, and that centralization will streamline briefing on Abbott's preemption defenses. It declined to put the Abbott cases before the judge handling Boston Scientific, writing that "Little efficiency will be gained by placing SCS device MDLs against multiple manufacturers before one judge." Centralization says nothing about whether the Abbott claims have merit. The November 2026 JPML report lists 27 pending actions in MDL-3194. For the docket's JPML statistics, see the MDL-3194 page.

Devices

Abbott spinal cord stimulator devices reported in the litigation include the Proclaim XR, Proclaim Plus, Proclaim DRG, and Eterna systems. Device lists are drawn from manufacturer product lines and reporting rather than from a court exhibit, and the specific device you had is recorded in your implant and device records.

The filing deadline is the urgent issue

The single most useful thing to know about timing comes from a July 14, 2026 order by Judge Patrick Schiltz in the District of Minnesota. He dismissed three of four plaintiffs as time-barred under one-year state limitations periods in Kentucky and Tennessee, and held that the clock starts on inquiry notice, which he located at the earlier of being advised to turn the device off or the onset of dramatic new symptoms after implant. None of those plaintiffs had an explant, and revision or explant surgery was not treated as the trigger. This contradicts the two-to-four-year timeline advertised on many firm pages. Deadlines vary by state and this analysis will not apply everywhere, but treat the timeline as urgent.

Frequently Asked Questions

Is there an Abbott spinal cord stimulator MDL?
Yes. On October 2, 2026, after its September 24 hearing session, the JPML centralized the Abbott spinal cord stimulator cases as MDL-3194, In re: Abbott Laboratories Spinal Cord Stimulator Products Liability Litigation, in the Northern District of Illinois before Judge Lindsay C. Jenkins. Abbott opposed centralization. An earlier request had been denied on a procedural technicality rather than on the merits: all four Abbott cases then before the Panel were pending in a single district, and the federal centralization statute requires actions pending in different districts. The fresh petition, filed June 22, 2026, was granted. MDL-3194 is separate from MDL-3181 (Boston Scientific) and MDL-3195 (Nevro). The November 2026 JPML report lists 27 pending actions in MDL-3194.
What did Abbott recall in 2023?
On July 18, 2023 Abbott issued a recall that the FDA classified as Class I. Class I is the FDA’s most serious category, used where a device could cause serious injury or death. The recall concerned a firmware problem that could prevent the device from exiting MRI mode, leaving the stimulation off. Abbott’s recall covered 155,028 U.S. devices and was associated with 186 reported incidents and 73 injuries, with no deaths. Figures circulating online of roughly 197,000 devices or 76 injuries do not match the FDA record. Abbott’s is not the only Class I spinal cord stimulator recall: in 2026 the FDA also classified Boston Scientific’s removal of unused Infinion CX leads as Class I.
Were there other Abbott recalls?
Yes. Beyond the 2023 Class I recall, Abbott had a Class II recall in May 2024 related to the interval between the elective replacement indicator and end of service, and a Class II recall in October 2025 involving Eterna Bluetooth functionality. Separately, an April 17, 2026 urgent medical device correction described as a Surgery Mode issue has been reported, but it does not yet have an FDA-classified recall record, so we describe it as an unclassified correction rather than a recall.
How long do I have to file an Abbott spinal cord stimulator claim?
The deadline may be shorter than commonly advertised. In a July 14, 2026 order in the District of Minnesota, Judge Patrick Schiltz dismissed three of four plaintiffs as time-barred under one-year state limitations periods, holding the clock starts on inquiry notice, at the earlier of being advised to turn the device off or the onset of dramatic new symptoms after implant. Deadlines vary by state and that analysis will not apply everywhere, but anyone considering a claim should treat the timeline as urgent and speak with a licensed attorney promptly.
Have there been any Abbott spinal cord stimulator settlements or verdicts?
No. There has never been a jury verdict or a settlement against Abbott in spinal cord stimulator product liability litigation. Any specific settlement figure or average circulating online is a projection with no verifiable source behind it, and we do not publish such figures.

Sources & References

7 sources cited

• FDA Medical Device Recall Database: Abbott SCS Class I recall (July 18, 2023) and Class II recalls (May 2024, October 2025)

• JPML transfer order creating MDL-3181 (June 5, 2026), including the Section 1407 footnote on the Abbott cases

• JPML Hearing Session Order (filed August 14, 2026) setting the Abbott centralization motion for the September 24, 2026 hearing session

• JPML Transfer Order, MDL No. 3194, In re: Abbott Laboratories Spinal Cord Stimulator Products Liability Litigation (October 2, 2026; September 2026 hearing session)

• FDA recall notice, Boston Scientific Infinion CX leads (Class I; September 3, 2026)

• Schiltz order, U.S. District Court, District of Minnesota (July 14, 2026)

• Abbott urgent medical device correction reporting (April 17, 2026), pending FDA classification

• Judicial Panel on Multidistrict Litigation: MDL statistics

Attorney Advertising. The information on this page is provided for general informational purposes only and does not constitute legal advice. No attorney-client relationship is created by accessing or using this content.

Every case is unique, and results depend on the specific facts and circumstances involved. Past settlement amounts and case outcomes do not guarantee similar results in your case. If you believe you have a legal claim, you should consult with a licensed attorney in your jurisdiction who can evaluate your specific situation.

Read our full disclaimer · Privacy Policy · Terms of Use